Contraception
Volume 81, Issue 2 , Pages 143-149 , February 2010

Feasibility of telephone follow-up after medical abortion

  • Lisa K. Perriera

      Affiliations

    • University of Pittsburgh School of Medicine, Department of Obstetrics, Gynecology and Reproductive Sciences, Pittsburgh, PA 15213, USA
    • Corresponding Author InformationCorresponding author. Case Western Reserve University School of Medicine, Department of Obstetrics and Gynecology, University Hospitals, MacDonald Women's Hospital 11100 Euclid Ave. Cleveland OH 44106, USA. Tel.: +1 216 844 3888; fax: +1 216 844 3348.
    • ,
  • Matthew F. Reeves

      Affiliations

    • University of Pittsburgh School of Medicine, Department of Obstetrics, Gynecology and Reproductive Sciences, Pittsburgh, PA 15213, USA
    • Magee-Womens Research Institute, Pittsburgh, PA 15213, USA
    • ,
  • Beatrice A. Chen

      Affiliations

    • University of Pittsburgh School of Medicine, Department of Obstetrics, Gynecology and Reproductive Sciences, Pittsburgh, PA 15213, USA
    • ,
  • Heather L. Hohmann

      Affiliations

    • University of Pittsburgh School of Medicine, Department of Obstetrics, Gynecology and Reproductive Sciences, Pittsburgh, PA 15213, USA
    • ,
  • Jennifer Hayes

      Affiliations

    • University of Pittsburgh School of Medicine, Department of Obstetrics, Gynecology and Reproductive Sciences, Pittsburgh, PA 15213, USA
    • ,
  • Mitchell D. Creinin

      Affiliations

    • University of Pittsburgh School of Medicine, Department of Obstetrics, Gynecology and Reproductive Sciences, Pittsburgh, PA 15213, USA
    • Magee-Womens Research Institute, Pittsburgh, PA 15213, USA
    • University of Pittsburgh Graduate School of Public Health, Department of Epidemiology, Pittsburgh, PA 15261, USA

Received 20 June 2009 ,Revised 24 August 2009 ,Accepted 25 August 2009.

References 

  1. Mifeprex Package Insert, Danco Laboratories, July 19. 2005.
  2. Schaff EA, Fielding SL, Westhoff C, et al. Randomized trial of vaginal misoprostol administered 1, 2, or 3 days after mifepristone for early medical abortion (<56 days gestation). JAMA. 2000;284:1948–1953
  3. Schaff EA, Fielding SL, Westhoff C. Randomized trial of oral versus vaginal misoprostol at one day after mifepristone for early medical abortion. Contraception. 2001;64:81–85
  4. Fiala C, Safar P, Bygdeman M, Gemzell-Danielsson K. Verifying the effectiveness of medical abortion; ultrasound versus hCG testing. Eur J Obstet Gynecol Reprod Biol. 2003;109:190–195
  5. Godfrey EM, Anderson A, Fielding SL, Creinin MD. Clinical utility of urine pregnancy assays to determine medical abortion outcome is limited. Contraception. 2007;75:378–382
  6. Reeves MF, Fox MC, Lohr PA, Creinin MD. Endometrial thickness following medical abortion is not predictive of subsequent surgical intervention. Ultrasound Obstet Gynecol. 2009;34:104–109
  7. Benson J, Clark KA, Gerhardt A, Randall L, Dudley S. Early abortion services in the United States: a provider survey. Contraception. 2003;67:287–294
  8. Joffe C. Reactions to medical abortion among providers of surgical abortion: an early snapshot. Fam Plann Perspect. 1999;31:35–38
  9. Creinin MD. Change in serum beta-human chorionic gonadotropin after abortion with methotrexate and misoprostol. Am J Obstet Gynecol. 1996;174:776–778
  10. Walker K, Schaff E, Fielding S, Fuller L. Monitoring serum chorionic gonadotropin levels after mifepristone abortion. Contraception. 2001;64:271–273
  11. Creinin MD, Vittinghoff E. Methotrexate and misoprostol vs misoprostol alone for early abortion. A randomized controlled trial. JAMA. 1994;272:1190–1195
  12. Schaff EA, Eisinger SH, Franks P, Kim SS. Combined methotrexate and misoprostol for early induced abortion. Arch Fam Med. 1995;4:774–779
  13. Pymar HC, Creinin MD, Schwartz JL. Mifepristone followed on the same day by vaginal misoprostol for early abortion. Contraception. 2001;64:87–92
  14. Rossi B, Creinin MD, Meyn LA. The ability of the clinician and patient to predict the outcome of mifepristone and misoprostol medical abortion. Contraception. 2004;70:313–317
  15. Lohr P, Reeves M, Hayes J, Harwood B, Creinin M. Oral mifepristone and buccal misoprostol administered simultaneously for abortion: a pilot study. Contraception. 2007;76:215–220
  16. Creinin MD, Fox M, Teal S, Chen A, Schaff E, Meyn LA. Randomized comparison of misoprostol 6 to 8 hours versus 24 hours after mifepristone for abortion. Obstet Gynecol. 2004;103:851–859
  17. Winikoff B, Dzuba IG, Creinin MD, et al. Two distinct oral routes of misoprostol in mifepristone medical abortion. Obstet Gynecol. 2008;112(6):1303–1310
  18. Creinin MD, Schreiber CA, Bednarek P, Lintu H, Wagner MS, Meyn L. Mifepristone and misoprostol administered simultaneously compared with 24 hours apart for abortion. Obstet Gynecol. 2007;109:885–894
  19. Von Hertzen H, Honkanen H, Piaggio G, et al. WHO multinational study of three misoprostol regimens after mifepristone for early medical abortion I: efficacy. Br J Obstet Gynecol. 2003;110:808–818
  20. Creinin MD, Potter C, Holovanisin S, et al. Mifepristone and misoprostol and methotrexate/misoprostol in clinical practice for abortion. Am J Obstet Gynecol. 2003;188(3):664–669
  21. Schaff E, Fielding S, Eisinger S, Stadalius L, Fuller L. Low-dose mifepristone followed by vaginal misoprostol at 48 hours for abortion up to 63 days. Contraception. 2000;61:41–46

☆ PRESENTATION: Oral presentation at Reproductive Health 2009, Hollywood, CA, USA, October 1, 2009.

PII: S0010-7824(09)00387-4

doi: 10.1016/j.contraception.2009.08.008

Contraception
Volume 81, Issue 2 , Pages 143-149 , February 2010

Article Tools

* Image Usage & Resolution